Modified Alginates Reduce Fibrosis in Implanted Devices
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing biomaterials used in medical devices elicit a foreign body response, leading to fibrous encapsulation and device failure, due to their inability to prevent inflammatory reactions and fibrosis.
Innovation Solution
Chemically modified alginates with enhanced biocompatibility and anti-fibrotic properties are developed, which can be used to coat or encapsulate materials and devices, reducing the foreign body response and promoting long-term compatibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional biomaterials are used for medical devices, then device structure and function can be achieved, but foreign body response and fibrous encapsulation occur leading to device failure
Solution Approach 1:
The patent applies parameter changes by chemically modifying alginate polymers through controlled introduction of hydrophobic groups and crosslinking sites. This transforms the polymer's physicochemical properties (hydrophobicity, crosslinking density) to create a surface that resists macrophage adhesion and fibrous encapsulation, thereby eliminating foreign body response while maintaining device structural integrity and longevity
Solution Approach 2:
The invention creates composite materials by combining modified alginate polymers with other biomaterials or coating substrates. The modified alginate forms a functional layer on device surfaces that provides anti-fibrotic properties while the underlying substrate maintains mechanical strength, achieving both device reliability and resistance to foreign body response
2Reliability
If alginate is used to encapsulate cells, then immunoisolation is achieved, but fibrous capsule formation isolates the device from host and causes failure
Solution Approach 1:
The patent modifies alginate parameters by introducing hydrophobic groups and crosslinking functionality to change the polymer's interaction with host tissues. This chemical modification transforms alginate from a material that provokes fibrosis to one that resists fibrous encapsulation, maintaining implant functionality while preventing fibrosis-induced isolation
Solution Approach 2:
The invention converts the naturally fibrotic response to alginate into a beneficial anti-fibrotic effect by chemical modification. The modified alginate actively prevents fibrous capsule formation that would otherwise isolate and fail the implant, turning a harmful material property into a protective function
3Reliability
If materials are coated with modified alginates, then biocompatibility is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-modifying alginate polymers with hydrophobic groups and crosslinking sites before application. This advance chemical preparation ensures that the coating material possesses inherent anti-fibrotic properties, simplifying the actual coating process and reducing the need for complex post-processing or specialized manufacturing equipment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified alginates significantly reduce fibrous capsule formation and inflammatory responses, ensuring better diffusion of nutrients and oxygen to encapsulated cells, thereby enhancing the longevity and effectiveness of implanted devices.
Implementation Method 1
Chemically modified alginates with enhanced biocompatibility and anti-fibrotic properties are developed, which can be used to coat or encapsulate materials and devices, reducing the foreign body response
Implementation Method 2
ensuring better diffusion of nutrients and oxygen to encapsulated cells
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.